IOVANCE BIOTHERAPEUTICS, INC. Available-for-sale Securities, Amortized Cost Basis
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Available-for-sale Securities, Amortized Cost Basis of $611.05 million as of 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2020-08-06
- 2020-06-30: Available-for-sale Securities, Amortized Cost Basis $611.05M.
- 2020-03-31: Available-for-sale Securities, Amortized Cost Basis $192.17M.
- 2019-12-31: Available-for-sale Securities, Amortized Cost Basis $292.42M.
- 2019-09-30: Available-for-sale Securities, Amortized Cost Basis $321.74M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2020-06-30 | $611.05M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $192.17M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $292.42M 10-Q · filed 2020-08-06 |
| 2019-09-30 | $321.74M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $325.04M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $383.84M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $385.27M 10-K · filed 2020-02-25 |
| 2017-06-30 | $14.73M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $40.10M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $59.72M 10-K · filed 2017-03-09 |
| 2016-09-30 | $86.22M 10-Q · filed 2016-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |